NCT00784979View on ClinicalTrials.gov

Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2012

Conditions
End Stage Renal Disease
Interventions
DRUG

CMVIG

400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks

Trial Locations (1)

33606

LifeLink HealthCare Institute, Tampa

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Tampa General Hospital

OTHER